Short answer: Likely yes, but viability depends on the modality and scope. Transformers already work well on many bio data types; the path of least resistance is to fine‑tune an existing bio foundation model rather than train from scratch.

Clarify your idea
- Which data? DNA/RNA sequences, proteins, small molecules, single‑cell (scRNA/ATAC/CITE‑seq), spatial transcriptomics, microscopy images, EHR/clinical text?
- What task? Prediction (e.g., variant effect, promoter activity), classification (cell type), retrieval/matching (enhancer–gene links), generation/design, or multimodal alignment?
- Scale/labels? Do you have large unlabeled data (pretrain) or limited labeled sets (fine‑tune)?
- Constraints? Compute budget, privacy/IRB, species, batch/lab heterogeneity.

What’s already viable (templates you can adapt)
- DNA/RNA sequences
  - Use DNABERT‑2/Nucleotide Transformer/Enformer embeddings for tasks like promoter/enhancer activity, TF binding, splice variant effects.
  - Tokenization: k‑mers; context length matters (2–200 kb for regulatory tasks).
  - Evaluate: AUROC/PR, motif recovery via attribution; OOD across cell lines/labs.
- Proteins
  - Use ESM‑2/ProtT5 embeddings for function, stability, variant effects, or design; ESMFold for structure guidance.
  - Evaluate: zero‑shot variant effect (Spearman vs DMS), family transfer, structure‑aware attributions.
- Single‑cell (scRNA/ATAC/CITE‑seq)
  - Fine‑tune Geneformer/scGPT for cell type, perturbation response, imputation, integration.
  - Handle batch effects explicitly (harmonization, domain adversarial heads).
  - Evaluate: ARI/NMI for clustering, label transfer accuracy, batch mixing, OOD tissues/donors.
- Microscopy images
  - ViT/ConvNeXt backbones; self‑supervision (DINO/MAE) + task‑specific heads (MIL for WSIs).
  - Evaluate: slide‑level AUROC, pixel/instance metrics, robustness across scanners/sites.
- Molecules
  - SMILES transformers (ChemBERTa/MolFormer) or graph transformers for property prediction/generation.
  - Evaluate: scaffold split performance, calibration, synthesizability constraints.
- Multimodal integration
  - Contrastive transformers (CLIP‑style) to align, e.g., histology images with gene expression, or scRNA with scATAC (paired CITE‑seq/10x Multiome).
  - Evaluate: cross‑modal retrieval R@K, zero‑shot transfer, biological plausibility (pathway enrichment).

Where novelty can be
- Cross‑dataset, cross‑species, or cross‑lab generalization with strong OOD guarantees.
- Unified transformers that join sequence + single‑cell state (regulatory sequence to cell‑type‑specific expression).
- Contrastive/self‑supervised pretraining that leverages weak supervision (ontologies like GO/Cell Ontology, PPI/GRN priors).
- Mechanistic interpretability that recovers motifs/networks or structure–function links, not just higher accuracy.
- Efficient long‑context or sparse attention for kilobase‑scale regulatory windows or whole‑slide images.

Minimal viable path (low compute)
- Pick one narrow task with public data and strong baselines.
  1) DNA example: fine‑tune DNABERT‑2 on splice‑site/cryptic‑splice prediction (e.g., COSMIC/Human Splicing datasets). Show motif recovery and OOD across chromosomes.
  2) Single‑cell example: fine‑tune Geneformer/scGPT for cell‑type label transfer across studies (train on one atlas, test on another). Add a small domain‑adversarial head to reduce batch effects.
  3) Multimodal example: CLIP‑style model on CITE‑seq (RNA ↔ surface proteins). Contrastive loss, evaluate cross‑modal retrieval and zero‑shot protein imputation.
- Compute: 1×A100/3090‑class GPU is typically enough for fine‑tuning; training from scratch usually isn’t necessary.
- Baselines: simple CNN/RNN or XGBoost on expert features; scVI/scanorama for single‑cell; k‑NN on pretrained embeddings.
- Validation: strict OOD splits (by lab/donor/species), calibration metrics, biological interpretability checks (motif/GO pathway enrichment, gradient maps).

Common pitfalls
- Batch effects and leakage across studies; always split by source.
- Tokenization/context mismatches (k‑mer choice, sequence length truncation).
- Overclaiming “discovery” without mechanistic validation; include attribution and external replication.
- Privacy/IRB and data governance for clinical/omics data.

If you share the exact data modality, target task, and what “mixing” entails (e.g., sequences + single‑cell + images?), I can propose a concrete model choice, dataset(s), baselines, and a 2–6 week experiment plan.